BCM
MBX

Bridgeway Capital Management’s MBX Biosciences MBX Stock Holding History

Bridgeway Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Sell
7,500
-2,500
-25% -$85K ﹤0.01% 1010
2025
Q4 		$315K Sell
10,000
-4,200
-30% -$102K 0.01% 921
2025
Q3 		$249K Sell
14,200
-15,000
-51% -$201K 0.01% 972
2025
Q2 		$333K Buy
+29,200
New +$297K 0.01% 846

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Bridgeway Capital Management's MBX Position: Q1 2026 in Review

Bridgeway Capital Management reduced its MBX Biosciences (MBX) stake by 25% in Q1 2026, selling an estimated $85K and leaving 7,500 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

Bridgeway Capital Management first reported a position in MBX in Q2 2025 and has held it in 4 quarters since. The position peaked at $333K in Q2 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Bridgeway Capital Management held 7,500 shares of MBX Biosciences worth $224K as of Q1 2026.
  • Bridgeway Capital Management sold 2,500 MBX Biosciences shares in Q1 2026, an estimated $85K.
  • MBX Biosciences made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1010 holding.
  • Bridgeway Capital Management first reported a position in MBX Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Bridgeway Capital Management's MBX Biosciences position peaked at $333K in Q2 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.